Biotech Stock Updates

We focus to look at key drivers of biotech stocks' price movement on 21 May 2025. UroGen Pharma (NASDAQ: URGN) announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 4–5 against the benefit-risk profile of its investigational therapy UGN-102 (mitomycin) for intravesical solution fo CEL-SCI Corporation (NYSE: CVM) announced that it intends to offer to sell shares of its common stock and/or pre-funded warrants in an underwritten public offering. Shares traded down 13% at US$3.95 during after hours Petros Pharmaceuticals (NASDAQ: PTPI) partnered with Innolitics to upgrade its SaaS platform by integrating AI, cybersecurity, and cloud-based capabilities. Innolitics, known for its work with Fortune 100 companies and Biodesix (NASDAQ: BDSX) shares traded higher after Jack Schulher bought 723,239 and 4,000,000 shares of the company at US$0.341 and US$0.2675, respectively, since last Friday. Shares closed up 46% at US$0.4. Jaguar Health (NASDAQ: JAGX) will raise capital via a direct offering of 246,306 shares at US$6.09/share, and a concurrent private placement of warrants for 492,612 shares at US$5.84/share. Shares closed down 27% at US NeurAxis (NYSE: NRXS) announced a US$5.0M direct offering, selling 1,538,461 common shares at US$3.25/share, priced at market under NYSE American rules. Shares closed down 20% at US$3.2. Quipt Home Medical (NASDAQ: QIPT) received an unsolicited, non-binding proposal from Forager Capital Management to acquire 100% of its common shares at US$3.10 per share. Shares closed down 9% at US$1.95.